Medical/Pharmaceuticals
Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma
SYDNEY, Dec. 4, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinical study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298). The res...
2021-12-04 21:00
5615
Henlius' 4th Biologics: Bevacizumab Biosimilar Hanbeitai Approved by National Medical Products Administration
SHANGHAI, Dec. 4, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that bevacizumab biosimilar Hanbeitai, developed and manufactured by Henlius independently, has been approved by the National Medical Products Administration (NMPA). It is indicated for the treatment of meta...
2021-12-04 01:51
7275
I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors
SHANGHAI and GAITHERSBURG, Md., Dec. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first two patients have been dosed in the U.S. p...
2021-12-03 21:00
4255
OrigiMed announced its strategic partnership with Janssen to develop clinical innovative solutions driven by data science
SHANGHAI, Dec. 3, 2021 /PRNewswire/ -- OrigiMed Co., Ltd. ("OrigiMed") announced that the company has signed a memorandum of understanding (MoU) on strategic collaboration with Janssen (China) Research and Development Center of Johnson & Johnson (China) Investment Co., Ltd. ("Janssen").Zili Li, M...
2021-12-03 17:01
6333
Biotheus' Bifunctional Therapeutic PM8001 has been Approved by the USFDA to Enter Phase II Studies
ZHUHAI, China, Dec. 3, 2021 /PRNewswire/ -- Biotheus Inc., has announced that its proprietary anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been approved by the USFDA (United States Food and Drug Administration) for conducting clinical phase II studies as part of an international m...
2021-12-03 16:23
2546
Mongolian Government To Build On COVID-19 Vaccine And Booster Success
* Mongolia secures nearly 70% vaccination rates and an overall casualty rate of only 0.3% * Successes against COVID-19 position country well for ambitious and progressive reforms as part of government's Vision 2050 agenda ULAANBAATAR, Mongolia, Dec. 3, 2021 /PRNewswire/ -- Mongolia is prepari...
2021-12-03 15:00
3338
Elekta's new sustainability-linked bond oversubscribed
STOCKHOLM, Dec. 3, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that it has issuedSEK 1.5 billion senior unsecured sustainability-linked bonds under its Medium Term Note Program (MTN-Program). One of the bonds, in the amount of SEK 1,150 million, has a maturity of 5 years with a coupon ...
2021-12-03 14:54
4423
RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug List for SLE and Gastric Cancer Treatment
YANTAI, China, Dec. 3, 2021 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, today announced that two of its innovative drugs, a dual-targeted TACI-Fc fusion protein, Telitacicept (RC18) for treating systemic lupus erythematosus (SLE) and a novel antibody-dru...
2021-12-03 13:45
6432
Innovent and Lilly Announce Successful Expansion of Sintilimab in China National Reimbursement Drug List to Include Three Additional First-Line Indications
SAN FRANCISCO, INDIANAPOLIS, and SUZHOU, China, Dec. 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and ...
2021-12-03 12:37
5439
Ascletis Announces Inclusion in New Catalogue of China National Reimbursement Drug List (NRDL) of ASCLEVIR®/ GANOVO® Regimen, an All-oral Direct Anti-HCV Therapy
HANGZHOU, China and SHAOXING, China, Dec. 3, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that its all-oral direct anti-hepatitis C virus (HCV) ASCLEVIR® (Ravidasvir)/ GANOVO® (Danoprevir) regimen has been included in the Medicine Catalog for National Basic Medical Insu...
2021-12-03 12:05
6027
InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List
BEIJING, Dec. 2, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today that its BTK inhibitor orelabrutinib has been included in the updated National Reimbursement Drug List (NRDL) by the China National Healthcare Security Administration (NHSA). ...
2021-12-03 10:13
2879
Decode Genetics Publishes the Largest Ever Study of the Plasma Proteome
REYKJAVIK, Iceland, Dec. 3, 2021 /PRNewswire/ -- In a study published today in Nature genetics, scientists at deCODE genetics , a subsidiary of the pharmaceutical company Amgen, demonstrate how measuring the levels of a large number of proteins in plasma at population scale when combined with dat...
2021-12-03 03:26
4230
Hepagene Therapeutics Initiates the RISE Study, a Phase IIa Clinical Trial of HPG1860 in Patients with NASH
SHANGHAI, Dec. 2, 2021 /PRNewswire/ -- Hepagene Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on innovative therapies for patients with liver diseases, today announced that it has screened the first patient in theUSA for the RISE study, a Phase IIa clinical trial of HPG18...
2021-12-02 23:00
2163
MingMed Biotechnology Announces U.S. FDA Approval for IND Application of HPK1 Small Molecule Inhibitor PRJ1-3024, and Completion of Phase I Clinical Trials for Dry AMD Treatment Drug QA102
GUANGZHOU, China, Dec. 2, 2021 /PRNewswire/ -- MingMed Biotechnology, a clinical stage company dedicated to developing first-in-class pharmaceutical products, announced recently the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for PRJ1-3024, a ...
2021-12-02 22:00
2307
Clarity and Cardinal Health enter into Agreement for Targeted Copper Theranostics
SYDNEY, Dec. 2, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, and Cardinal Health (NYSE: CAH), are pleased to announce that the companies have entered ...
2021-12-02 21:58
2876
Rayence's Low-Dose Detector "GreenON" Receives Critical Acclaim at RSNA 2021
SEOUL, South Korea, Dec. 2, 2021 /PRNewswire/ -- Rayence(www.rayence.com
2021-12-02 21:30
2954
Joint CUHK-HKU study discovers efficacy of COVID-19 vaccines correlates with a probiotic bacterium, Bifidobacterium adolescentis
HONG KONG, Dec. 2, 2021 /PRNewswire/ -- The Centre for Gut Microbiota Research of the Faculty of Medicine at TheChinese University of Hong Kong (CU Medicine) is among the first in the world to discover that germs in our gut (gut microbiota) modulate our immunity and disease severity in COVID-19. ...
2021-12-02 21:00
16861
DiNovA Medtech Announces Mr. Yaniv Kirma to Join as DiNovA Israel Incubator's Chief Operating Officer
CAESAREA, Israel, Dec. 2, 2021 /PRNewswire/ -- DiNovA Medtech, a leading medical devices incubator inChina ("DiNovA"), is pleased to announce Mr. Yaniv Kirma, to come on board as Chief Operating Officer of DiNovA Israel Incubator ("DiNovA Israel"). Mr. Kirma will join force with Chief Medical Off...
2021-12-02 16:00
2372
Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test
- RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women - Results have already led to updated NCCN Guidelines® for breast cancer - New RxPONDER results to be fea...
2021-12-02 16:00
3537
DiNovA Medtech Announces Mr. Yaniv Kirma to Join as DiNovA Israel Incubator's Chief Operating Officer
CAESAREA, Israel, Dec. 2, 2021 /PRNewswire/ -- DiNovA Medtech, a leading medical devices incubator inChina ("DiNovA"), is pleased to announce Mr. Yaniv Kirma, to come on board as Chief Operating Officer of DiNovA Israel Incubator ("DiNovA Israel"). Mr. Kirma will join force with Chief Medical Off...
2021-12-02 16:00
2501
Week's Top Stories
Most Reposted
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 281 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
Allianz Partners unveils next-generation travel insurance platform to help partners navigate changing landscape
[Picked up by 269 media titles]
2026-09-28 07:30
ViewSonic Launches VG1457 Dual-Screen Portable Monitor for Productivity Anywhere
[Picked up by 267 media titles]
2026-09-30 10:50
Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 267 media titles]
2026-10-01 10:00
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
22899
